LLB BA - Kamada General VP

KMDA Stock  USD 5.89  0.08  1.38%   

VP

LLB BA is General VP of Kamada
Age 45
Address 2 Holzman Street, Rehovot, Israel, 7670402
Phone972 8 940 6472
Webhttps://www.kamada.com

Kamada Management Efficiency

The company has return on total asset (ROA) of 0.0316 % which means that it generated a profit of $0.0316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0705 %, meaning that it created $0.0705 on every $100 dollars invested by stockholders. Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.04. The current year's Return On Capital Employed is expected to grow to 0.03. At present, Kamada's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 194.2 M, whereas Non Currrent Assets Other are forecasted to decline to about 550.3 K.
Kamada currently holds 8.82 M in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Kamada has a current ratio of 2.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kamada's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 12 records

VP Age

Kipling ThackerLifecore Biomedical
69
MBA MSIronwood Pharmaceuticals
N/A
MPH MDIronwood Pharmaceuticals
N/A
Anthony CPAPhibro Animal Health
55
Meredith CookANI Pharmaceuticals
50
Meredith JDANI Pharmaceuticals
50
Mona DesaiPhibro Animal Health
N/A
William JDPrestige Brand Holdings
59
James HermanCumberland Pharmaceuticals
69
Shirley JDCollegium Pharmaceutical
40
Charles AtkinsonPerrigo Company PLC
N/A
Judith WeinsteinPhibro Animal Health
55
It operates in two segments, Proprietary Products and Distribution. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. Kamada operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 355 people. Kamada (KMDA) is traded on NASDAQ Exchange in USA. It is located in 2 Holzman Street, Rehovot, Israel, 7670402 and employs 378 people. Kamada is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Kamada Leadership Team

Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Tsur, Co-Founder and Deputy Executive Chairman
LLB BA, General VP
Boris Gorelik, Vice Programs
Liron Reshef, Vice Resources
Chaime Orlev, Chief Officer
Yifat Esq, Gen Legal
Amir London, Chief Officer
Ariella Raban, VP HR
Eran Nir, Chief Officer
Hanni Neheman, Vice Sales
Shavit Beladev, Vice Plasma
Jon Knight, Vice Operations

Kamada Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kamada. If investors know Kamada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kamada listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1
Earnings Share
0.27
Revenue Per Share
2.837
Quarterly Revenue Growth
0.134
Return On Assets
0.0316
The market value of Kamada is measured differently than its book value, which is the value of Kamada that is recorded on the company's balance sheet. Investors also form their own opinion of Kamada's value that differs from its market value or its book value, called intrinsic value, which is Kamada's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kamada's market value can be influenced by many factors that don't directly affect Kamada's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kamada's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kamada is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kamada's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.